Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa).
Anthony T. C. Chan
No relevant relationships to disclose
Stephen Lam Chan
No relevant relationships to disclose
Wing Ming Ho
No relevant relationships to disclose
Wilson Lau
No relevant relationships to disclose
Frankie Mo
No relevant relationships to disclose
Edwin P. Hui
No relevant relationships to disclose
Charles Chan
No relevant relationships to disclose
Annette Poon
No relevant relationships to disclose
Rasalkar Dattatray
No relevant relationships to disclose
S. C. Cesar Wong
No relevant relationships to disclose
Ka Fai To
No relevant relationships to disclose
Ann Dorothy King
No relevant relationships to disclose
Anil Tejbhan Ahuja
No relevant relationships to disclose
Brigette Ma
No relevant relationships to disclose